Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study
X Pu, Y Zhou, Y Kong, B Chen, A Yang, J Li, K Li, Y Xu… - Bmc Cancer, 2023 - Springer
Background About 10% of non-small cell lung cancer (NSCLC) patients with epidermal
growth factor receptor (EGFR) mutations are harbored as uncommon mutations. This study …
growth factor receptor (EGFR) mutations are harbored as uncommon mutations. This study …
[HTML][HTML] Efficacy of dacomitinib in patients with non-small cell lung cancer carrying complex EGFR mutations: a real-world study
HS Li, JL Li, X Yan, HY Xu, LQ Zhou… - Journal of Thoracic …, 2022 - ncbi.nlm.nih.gov
Background Dacomitinib is a first-line treatment for patients with non-small cell lung cancer
(NSCLC) harboring common epidermal growth factor receptor (EGFR) mutations; however …
(NSCLC) harboring common epidermal growth factor receptor (EGFR) mutations; however …
Dacomitinib for advanced non-small cell lung cancer patients harboring major uncommon EGFR alterations: a dual-center, single-arm, ambispective cohort study in …
HS Li, GJ Yang, Y Cai, JL Li, HY Xu, T Zhang… - Frontiers in …, 2022 - frontiersin.org
Objective: Dacomitinib has been approved for non-small-cell lung cancer (NSCLC) patients
harboring classical epidermal growth factor receptor (EGFR) mutations; however, clinical …
harboring classical epidermal growth factor receptor (EGFR) mutations; however, clinical …
A real‐world study of dacomitinib in later‐line settings for advanced non‐small cell lung cancer patients harboring EGFR mutations
HS Li, JY Zhang, X Yan, HY Xu, XZ Hao… - Cancer …, 2022 - Wiley Online Library
Objective Dacomitinib has been approved for the first‐line treatment of non‐small cell lung
cancer (NSCLC) carrying classical epidermal growth factor receptor (EGFR) mutations; …
cancer (NSCLC) carrying classical epidermal growth factor receptor (EGFR) mutations; …
Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non–small cell lung cancer: A multicenter retrospective …
H Tanaka, H Sakamoto, T Akita, F Ohyanagi… - Thoracic …, 2022 - Wiley Online Library
Background Dacomitinib is the second‐generation epidermal growth factor receptor (EGFR)‐
tyrosine kinase inhibitor (TKI) for mutant non–small cell lung cancer (NSCLC). EGFR‐TKIs …
tyrosine kinase inhibitor (TKI) for mutant non–small cell lung cancer (NSCLC). EGFR‐TKIs …
[HTML][HTML] Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label …
Y Cheng, TS Mok, X Zhou, S Lu, Q Zhou, J Zhou, Y Du… - Lung Cancer, 2021 - Elsevier
Objectives To compare efficacy and safety of dacomitinib versus gefitinib as first-line therapy
for EGFR mutation-positive advanced NSCLC in Asian patients enrolled in the ongoing …
for EGFR mutation-positive advanced NSCLC in Asian patients enrolled in the ongoing …
Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non–small-cell lung cancer and EGFR …
TS Mok, Y Cheng, X Zhou, KH Lee… - Journal of Clinical …, 2018 - ascopubs.org
Purpose ARCHER 1050, a randomized, open-label, phase III study of dacomitinib versus
gefitinib in treatment-naïve patients with advanced non–small-cell lung cancer (NSCLC) and …
gefitinib in treatment-naïve patients with advanced non–small-cell lung cancer (NSCLC) and …
Updated overall survival in a randomized study comparing dacomitinib with gefitinib as first-line treatment in patients with advanced non-small-cell lung cancer and …
TS Mok, Y Cheng, X Zhou, KH Lee, K Nakagawa… - Drugs, 2021 - Springer
Background ARCHER 1050, an ongoing, randomized, open-label, phase III trial of
dacomitinib versus gefitinib in newly diagnosed patients with advanced non-small-cell lung …
dacomitinib versus gefitinib in newly diagnosed patients with advanced non-small-cell lung …
Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
J Zhang, Y Wang, Z Liu, L Wang, Y Yao, Y Liu… - Thoracic …, 2021 - Wiley Online Library
Background Dacomitinib is a second‐generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) which is superior to first‐generation EGFR TKI in ARCHER …
tyrosine kinase inhibitor (TKI) which is superior to first‐generation EGFR TKI in ARCHER …
[HTML][HTML] The treatment of patients with non-small cell lung cancer carrying uncommon EGFR mutations, HER2 mutations, or brain metastases: a systematic review of …
LL Yang, XZ Luo, LL Xie, XZ Lei… - Translational Cancer …, 2023 - ncbi.nlm.nih.gov
Background Accumulating evidence has shown that dacomitinib has potential activities for
patients with non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth …
patients with non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth …
相关搜索
- safety of dacomitinib egfr mutation
- egfr mutations treatment of patients
- brain metastases dacomitinib in patients
- egfr mutations brain metastases
- egfr mutations dacomitinib in patients
- egfr mutations efficacy of dacomitinib
- efficacy and safety egfr mutation
- her2 mutations treatment of patients
- brain metastases efficacy of dacomitinib
- brain metastases treatment of patients